<i>p</i>53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy

Sunada, Fumiko; Itabashi, Michio; Ohkura, H; Okumura, Toshiyuki

doi:10.3748/wjg.v11.i36.5696

Cited by 23 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MT upregulation was detected in medulloblastoma and rhabdomyosarcoma cells with induced resistance to the alkylating drug BCNU [60]. Esophageal carcinomas which do not express MT, respond well to chemoradiotherapy (5-fluorouracil and cisplatin) while cancers with high MT expression are resistant [61]. Women with breast carcinoma treated with chemotherapy (cyclophosphamide, methotrexate, 5 fluorouracil or doxorubicin) had significantly longer survival if their tumours had lower MT expression [42].…”

Section: Discussionmentioning

confidence: 99%

Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker

Kruseová

Hynek

Adam

et al. 2013

IJMS

View full text Add to dashboard Cite

Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry–Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker

Kruseová

Hynek

Adam

et al. 2013

IJMS

View full text Add to dashboard Cite

show abstract

“…13,15 They can protect the cells against UV ⁄ ionic radiation and cytotoxic alkylating agents, modulate oxygen free radicals and nitric oxide and inhibit apoptosis. [16][17][18][19][20][21][22][23] In the last decade several reports have shown MT overexpression to be a useful prognostic factor for tumour progression and drug resistance in a variety of cancers such as ovarian cancer, renal cell carcinoma, breast cancer, non-small cell lung carcinoma, acute lymphoblastic leukaemia, pancreatic carcinoma and carcinoma of the gallbladder. [24][25][26][27][28][29] Similar results have been found in smaller retrospective studies in melanoma and non-melanomatous skin cancers.…”

mentioning

confidence: 99%

Metallothionein overexpression, a highly significant prognostic factor in thin melanoma

Weinlich

Zelger

2007

Histopathology

View full text Add to dashboard Cite

“…As far as we know, MT are involved in many physiological and pathophysiological processes such as the intracellular storage, transport and metabolism of heavy metal ions; they regulate essential trace metal homeostasis and play a protective role in heavy metal detoxification reactions (Miles et al, 2000;Simpkins, 2000). They can protect cells against UV-/ionic radiation (Hansen et al, 1997;Hanada et al, 1998;Reeve et al, 2000) as well as cytotoxic alkylating agents including chemotherapeutics (Chin et al, 1993;Hishikawa et al, 1997;Okazaki et al, 1998;Sunada et al, 2005), modulate oxygen free radicals and nitric oxide and inhibit apoptosis (Tsangaris and Tzortzatou-Stathopoulou, 1998). The synthesis of MT is induced by group II heavy metal ions as well as by endogenous factors such as glucocorticoids, cytokines (interleukin (IL)-1 or IL-6, interferon g (IFNg), tumour necrosis factor a (TNF-a)) or vitamin D 3 (Karin et al, 1985;Karasawa et al, 1987;Schroeder and Cousins, 1990;Sato and Sasaki, 1992;Nishimura et al, 2000).…”

mentioning

confidence: 99%

Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients

et al. 2006

View full text Add to dashboard Cite

Metallothioneins (MT) are ubiquitous, intracellular small proteins with high affinity for heavy metal ions. In the last decades, it was shown that MT overexpression in a variety of cancers is associated with resistance to anticancer drugs and is combined with a poor prognosis. In this prospective study, we examined the role of MT overexpression in melanoma patients as a prognostic factor for progression and survival. Between 1993 and 2004, 3386 patients with primary cutaneous melanoma were investigated by using a monoclonal antibody against MT on routinely fixed, paraffin-embedded tissues. In all, 1270 patients could be followed up for further statistical analysis (Fisher's exact test, Mantel -Haenszel w 2 test, Kaplan -Meier curves). The MT data of disease-free interval and overall survival were compared univariately and multivariately in Cox regression analysis. Immunohistochemical overexpression of MT in tumour cells of patients with primary melanoma (310 of 1270; 24.4%) was associated with a higher risk for progression (117 of 167; 70.1%) and reduced survival (80 of 110; 72.7%) of the disease (Po0.0001). Similarly, Kaplan -Meier curves gave highly significant disadvantages for the MT-positive group. Univariate analysis (relative risk 7.4; 95% confidence interval (CI) 5.2 -10.2; Po0.0001 for progression; relative risk 7.1; 95% CI 4.7 -10.9; Po0.0001 for survival), as well as multivariate analysis with other prognostic markers resulted in MT overexpression as a highly significant and independent factor for prognosis in primary melanoma.

show abstract

p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy

Abstract: Esophageal squamous cell carcinomas with negative p53, positive CDC25B, and negative MT expressions respond well to CRT. Even with p53 positivity, if with CDC25B positivity, CRT can be expected.

Cited by 23 publications

References 30 publications

Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker

Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker

Metallothionein overexpression, a highly significant prognostic factor in thin melanoma

Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients

Contact Info

Product

Resources

About